Envista Q2 revenue $682M (+5.6% core); raises FY adjusted EPS guidance to $1.05-$1.15

Envista Holdings Corp

2025-Q2 EPS reported $0.26 revenue$1,299,000,000

Q2 net income $26M vs loss of $1,152M a year ago; adjusted EPS $0.26 (+136% YoY).
Core sales growth 5.6% YoY across all businesses and geographies, including Nobel Biocare in North America.
FY2025 guidance raised: core sales growth 3-4% (prior 1-3%), adjusted EPS $1.05-$1.15 (prior $0.95-$1.05).
Repurchased 4.8M shares for ~$82M in Q2; $150M remaining under buyback program.
YTD operating cash flow $89M, free cash flow $71M, down from $133M and $116M in H1 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.